Abstract

One of the factors of osteoarthritis is obesity, which is now considered to be one of the major health problems around the world. Patients with osteoarthritis have a high comorbidity index. Medicamental therapy of patients with osteoarthritis and comorbid course of steatohepatitis is associated with additional risks such as hepatotoxic effects of drugs that patients take.Purpose: to review scientific articles which cover information on effectiveness of using drugs based on guaric acid to reduce excess body weight.Conclusion. Increased accumulation of visceral adipose tissue is one of the main pathogenetic factors contributing to development of osteoarthritis, steatosis and steatohepatitis. Therefore, drugs aimed at reducing excess body weight should take a leading place in the complex therapy of patients. Such drugs can contribute to reducing early disability of population, optimizing the quality of life indicators, and total life expectancy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.